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1  | INTRODUC TION
The most typical cytogenetic aberration in de novo myelodysplastic 
syndromes (MDS) is isolated del(5q), an interstitial deletion within 
the chromosome 5 long arm, which is the hallmark of refractory 
anaemia, macrocytosis, normal or high platelet count, erythroid hy-
poplasia, non- lobulated megakaryocytes, and relatively good prog-
nosis. LEN was recognised as efficacious therapy as it suppresses 
del(5q) clonal cells and acts on the erythroid compartment to im-
prove haemoglobin levels, leading to an 83% erythroid response rate 
and durable transfusion independence.1 Cytogenetic response rates 
were much higher in patients with isolated del(5q) than in patients 
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Abstract
Objective: The most typical cytogenetic aberration in myelodysplastic syndromes is 
del(5q), which, when isolated, is associated with refractory anaemia and good prog-
nosis. Based on high rates of erythroid response and transfusion independence, 
Lenalidomide (LEN) became the standard treatment. This multi- centre study was de-
signed to supplement Italian Registry data on LEN by addressing prescription, admin-
istration appropriateness, haematological and cytogenetic responses and disease 
evolution.
Methods: MORE study was an observational, non- interventional, multi- centre, retro-
spective and prospective study. Cases were recruited from 45 Haematological 
Centres throughout Italy. Data were collected from the Italian National Registry for 
Lenalidomide administration and supplemented by a MORE data form.
Results: Data from 190/213 patients were analysed. In all, 149 had been diagnosed 
by conventional cytogenetics (GROUP A) and 41 only by FISH (GROUP B). Overall 
erythroid response was obtained in 92.8% of cases. Overall cytogenetic remission 
was achieved in 22.6% of cases. Disease progression occurred in 15.6% of cases. 
Clonal cytogenetic evolution characterised progression to AML but not to higher risk 
MDS.
Conclusions: Erythroid response to Lenalidomide was similar in MDS with isolated 
del(5q) and with del(5q) plus one anomaly. Progression to AML or higher risk MDS 
showed different cytogenetic features.
K E Y W O R D S
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with del(5q) in complex karyotypes.2 The European MDS 004 study 
confirmed these data, recommending 10 mg LEN every 21 days in 
28- day cycles.3
After LEN was approved by the Food and Drug Administration 
(USA) and by the European Medicines Agency, administration under 
the Italian National Health Service was limited to patients with 
del(5q), whether isolated or not, and low or intermediate- 1 risk MDS 
(LOW or INT- 1 according to the IPSS score).4 They were enrolled in 
the Italian National Drug Agency Registry (AIFA, Agenzia Italiana 
Farmaco), which monitors administration of drugs that are still under 
investigation.
The present multi- centre study was designed to supplement 
Registry data on LEN by addressing prescription and administration 




Inclusion Criteria for the AIFA LEN Registry were as follows: LOW 
or INT- 1 MDS; transfusion- dependent anaemia (at least 2 units of 
packed RBCs in 8 weeks prior to starting LEN treatment); 5q de-
letion, whether isolated or associated with other chromosomal 
abnormalities.
2.2 | Study design
This observational, non- interventional, multi- centre, retro-
spective/prospective cohort study was registered as MORE 
(ClinicalTrials.gov NCT01347944) and designed as follows: collec-
tion of retrospective data on patients that had been enrolled in 
the Registry from October 31, 2008 to May 20, 2010; collection 
of prospective data as patients were recruited to the study from 
May 21, 2010 to June 13, 2012 (Figure S1); integration of both da-
tabases using a new MORE data form. All subjects in the Registry, 
who had undergone at least one cycle of LEN, were included in the 
MORE study.
The present study included 45 Italian Haematological Centres: 
22 from northern Italy, 11 middle and 12 southern (Figure S2). The 
Ethics Committee of each participating centre approved the study.
All data were independently collected from AIFA Registry 
through CINECA, a non- profit Inter- university Consortium for data 
collection, processing and statistical analysis. Data were monitored 
by CRO (MeDePha, Via Aosta 4/A, 20155, Milano), a data manage-
ment centre that organised, and was responsible for, inter- centre 
contacts, checked patient electronic Continuous Reinforcement 
Schedules (e- CRFs) and replied to e- Queries. A Scientific Steering 
Committee focused on centre compliance with procedures and 
checked data analysis.
Patients were divided into Group A, who underwent conven-
tional cytogenetic testing, and Group B, who underwent only FISH 
(Table 1). Two groups were analysed separately according to LEN 
dosage: 10 mg/d vs 5 mg/d (Table S1).
The primary study objectives were to determine prescrip-
tion and administration appropriateness and to assess clinical, 
TABLE  1 Demographics, MDS classification according to IPSS, 







Female 105 (70,5%) 25 (61,0%)
Male 44 (29,5%) 16 (39,0%)
Age
Median 75 71
Range [38; 95] [41; 87]
FAB Classification
Refractory Anaemia 105 (70.5%) 24 (58,5%)
Refractory Anaemia with 
ringed sideroblasts
2 (1.3%) 0
Refractory Anaemia with 
excess of blasts
17 (11.4%) 3 (7.3%)
Missing 25 (16,8%) 14 (34.1%)
WHO Classification
Refractory Anaemia 9 (6%) 3 (7.3%)
Refractory Anaemia with 
excess of blasts- 1
15 (10.1%) 3 (7.3%)
Refractory Anaemia with 





25 (16.8%) 5 (12.2%)
MDS- 5q 79 (53%) 26 (63.4%)
MDS- Unclassificable 3 (2%) 0
Missing 17 (11.4%) 4 (9.8%)
IPSS Classification
Low 69 (46.3%) 20 (48.8%)
Intermediate - 1 80 (53.7%) 21 (51.2%)
WPSS Classification
Very low 7 (4.7%) 2 (4.9%)
Low 51 (34.2%) 12 (29.3%)
Intermediate 16 (10.7%) 2 (4.9%)
High 8 (5.4%) 1 (2.4%)
Missing 67 (45%) 24 (58.5%)
Karyotype (only for Group A)
5q isolated 122 (81.9%) NA
5q not isolated 25 (16.8%) NA
Complex 2 (1.3%) NA
LEN cycles (median)
12 [5;24] 13 [4;34]
LEN, Lenalidomide.
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haematological and cytogenetic responses to LEN in- depth, accord-
ing to International Working Group criteria.5
Secondary objectives were to evaluate diagnostic approaches; to 
monitor cytogenetic and haematological changes during the course 
of disease; to identify subgroups with significant prognostic features 
and monitor LEN safety and tolerability.
Data analysis was conducted at predetermined time- points: 
after 4- 6 cycles of treatment; after 8- 12 cycles; at last follow- up 
and/or at the end of treatment. Only the cases with complete in-
formation at the three time- points entered both univariate and 
multivariate analyses. A total of 9 clinical variables were consid-
ered: bone marrow blasts, MCV, haemoglobin level, neutrophil 
count, ferritin levels, platelet count, Abnormal Localisation of 
Immature Precursors (ALIP), megakaryocytic dysplasia and bone 
marrow fibrosis (Table S2). For safety and toxicity assessment, fre-
quency of patients with any adverse events such as neutropenia, 
thrombocytopenia or infections, early withdrawal, hospitalisa-
tions were reported.
2.3 | Statistical Analysis
Descriptive statistics (mean, SD, median, range and inter- quartile 
range) were calculated for all continuous variables. Frequency dis-
tributions were calculated for categorical variables (disease, risk cat-
egory, haematological and cytogenetic profiles over time, response 
to LEN, disease progression). The t test for continuous variables and 
the chi- square test for categorical variables were used to analyse 
inter- group differences (unless otherwise stated, all P values are 
intended as two- tailed). Kaplan- Meier survival curves were calcu-
lated using time- to- event variables and the log- rank test for group 
comparison. Univariate logistic regression analyses evaluated some 
baseline variables and prognostic factors including blast and plate-
let counts, cytogenetic complexity at diagnosis, erythroid and/or 
cytogenetic response, to identify the prognostic factors associated 
with evolution to AML or higher risk MDS. Significant variables in 
univariate analysis (at alpha 0.1) were analysed in multivariate logis-
tic regression analysis.
The LOCF (Last Observation Carried Forward) method was ap-
plied to handle missing data.
2.4 | IT infrastructure and software
The web- based system for data collection was the CINECA 
AXMR® (Advanced Extended Multicentre Research) technology 
that was designed to manage clinical research processes. Data 
management (DB freezing, intermediate tables, views and mate-
rialised views in support of the analysis) was carried out using PL/
SQL Developer (Oracle Corporation database), which is based on 
the PL/SQL (Procedural Language/Structured Query Language) 
program.
Data analysis was performed using PL/SQL Developer and R 
open- source software, which is specific for statistical calculations 
and charting.
3  | RESULTS
3.1 | Study size, grouping and bias
In all, 213 patients were included in the registry during the study 
period (56 up to May 20, 2010 who provided retrospective data and 
134 afterwards who yielded both prospective and retrospective 
data).
Totally, 190/213 patients (M:F 60:130) were eligible for the 
study as they satisfied all inclusion criteria. At inclusion in the reg-
istry, 56 patients had been pre- treated with LEN, and the previous 
cycles were added by MORE integration. Starting doses of LEN 
were extremely heterogeneous; however, we were able to dis-
tinguish two groups: 59% of patients received 10 mg daily (in 21- 
day cycles or continuously) and 27% of patients were given 5 mg 
(in 21- day cycles or continuously) (Table S1). Moreover, 128/190 
cases (62%) stopped LEN treatment during the observation period 
(Table S3). Patients who had undergone only FISH testing (Group 
B) (41 patients, median age 71, 10 pre- treated) were analysed sep-
arately from those who underwent a full cytogenetic evaluation 
(Group A) (149 patients, median age 75, 46 pre- treated). On a total 
of 18.1% of patients with non- isolated 5q- , 1.3% had a complex 
karyotype, 16.8% one additional chromosomal abnormality. No 
significant inter- group (A vs B) differences emerged in patient de-
mographics, disease and risk categories or median time from diag-
nosis to LEN treatment (Table 1).
3.2 | Erythroid response
The complete erythroid response rate was 74.6% in group A and 
78.6% in group B after 4- 6 cycles, rising to 85.8% and 88.9%, re-
spectively, after 8- 12 cycles. The partial response rate was 11.5% 
in group A and 10.7% in group B after 4- 6 cycles, falling to 6.2% 
and 7.4%, respectively, after 8- 12 cycles as patients achieved com-
plete response (Figures 1, Table S4). In univariate analysis number 
of cycles >6, platelet count >100 000 and ALIP were significant 
both for complete and partial response; Hb and blast count re-
sulted significant only for overall response (P < .05) (Tables S5 and 
S6.). Only the duration of therapy reached the statistical signifi-
cance in multivariate analysis (P < .001) (Tables S7 and S8). No 
differences in overall and complete responses emerged in two 
treatment schedules.
3.3 | Cytogenetic response
Cytogenetic response was analysed and monitored only in patients 
who had undergone conventional cytogenetics for 5q- diagnosis 
(Group A). After 4- 6 cycles, the complete response rate was 7.8%, 
whereas the partial response rate was 2.4%. After 8- 12 cycles, the 
complete response rate rose to 13% and the partial to 9.6% (Figure 2, 
Table S4). Starting dosage at 10 mg LEN daily (P < .001) and eryth-
roid dysplasia (P < .05) significantly correlated with overall cytoge-
netic response. Only the starting dosage retains the statistical 
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significance in multivariate analysis (Table 3). None of these factors 
resulted significant for complete cytogenetic response in univariate 
analysis (data not shown). Within the 10 mg Group 60% of cases 
showed cytogenetic response at 24 months therapy (Figure 2C). 
However, dosage did not impact both leukaemia free survival (LFS) 
and overall survival (OS) (Figure S6).
3.4 | Disease progression
During the 44- month observation period (range: 0.5- 237), disease 
progression occurred in 15.6% of cases: 18/190 cases (9.5%) devel-
oped AML (Table 2) and 12 cases (6.1%) progressed to higher risk 
MDS (Table 3). We analysed separately cases developing AML and 
those progressing to higher risk MDS. Both subgroups were nega-
tive for any cytogenetic response to LEN treatment (Table 2). In 7/13 
Group A patients, AML diagnosis corresponded to clonal cytoge-
netic progression and acquisition of a complex karyotype, whereas 
complex cytogenetics never appeared in the subgroup evolving to 
higher risk MDS; in the last group, the del(5q) karyotype of diagnosis 
remained unchanged. In univariate analysis, cytogenetic and eryth-
roid response did not influence progression to AML or higher risk 
MDS (Figures S3 and S4). Significant differences emerged in time 
to progression (AML median 25 months, range 7- 89; MDS median 
54 months, range 15- 102; P .028) and number of LEN cycles (median: 
7.5 for AML and 19.5 for higher risk MDS, P .010). Other clinical and 
biological variables assessed in the present study include blast and 
platelet counts, cytogenetic complexity at diagnosis, erythroid and/
or cytogenetic response and time from MDS diagnosis and inclusion 
in the Registry. The only factor which achieved significance in our 
study was a blast count of >5% (P .010) in both univariate analysis 
(Figure S5) and multivariate analysis (P < .05) (Table S9).
3.5 | LEN safety and toxicity
During treatment, most patients had slight to moderate neutrope-
nia (75%; grade 3%- 4 59%) and thrombocytopenia (62%; grade 3%- 4 
21%). Grade 3- 4 Neutropenia led to drug discontinuation in fewer 
than 50% of cases and was treated with G- CSF in fewer than 10%. 
The incidences of neutropenia and thrombocytopenia were greater in 
the first 6 months of treatment. Infections (21%) were mostly upper 
respiratory tract infections. During the observation period, 13 pa-
tients (31.7%) were hospitalised because of infection. Five patients 
with platelet counts of >100 000/mmc and haemoglobin >10 g/dL in 
the early phase of treatment had deep venous thrombosis leading to 
LEN withdrawal. In one patient with HCV- related cirrhosis, liver tox-
icity led to early withdrawal after only 1 LEN cycle.
F IGURE  1 Time to development of complete (A) and overall 
erythroid response (B) in all patients (groups A and B). Time to 
complete erythroid response, only Group A (5q isolated vs 5q not 
isolated) (C) since treatment begin [Colour figure can be viewed at 
wileyonlinelibrary.com]
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4  | DISCUSSION
As far as we know, this is the first study on LEN use in the framework 
of a national registry, in which Haematology Units throughout Italy 
participated. Italian haematologists correctly selected patients and 
managed LEN administration. MORE integration data indicated a 
high response rate, supporting appropriate diagnosis and monitoring.
High erythroid response rates confirmed LEN had exerted its 
well- known effect in del(5q) MDS.1-3,6-8 This effect has been em-
phasised in a heterogeneous cohort of 716 MDS patients with 
71% overall erythroid response after 3 cycles of LEN; 83% of re-
sponders had MDS with del(5q).9 The drop of haemoglobin level we 
observed at the last follow- up was likely due to the relative high 
number of LEN suspension (98 cases) or disease progression (30 
cases). Haematological response was independent of cytogenetic 
remission, as demonstrated by the lower cytogenetic response rate 
compared to the erythroid, similarly to previous published series.3,10
Overall cytogenetic response in this study was very low com-
pared to the previous reported data. Indeed, major limitations of this 
study were treatment schedules that were heterogeneous for dura-
tion, continuous vs intermittent administration and individual dos-
age adjustments. No significant differences were found considering 
overall response after 6 cycles (P = .8). Instead LEN dosage, similarly 
to that reported in pivotal European MDS- 004,3 influenced cyto-
genetic response as the 10 mg initial dosage predicted cytogenetic 
response. Notably in the group of patients treated by long- standing 
10 mg dosage, cytogenetic response increased to 60%.
The impact of 5q- plus another anomaly on the erythroid re-
sponse rate in low and intermediate- 1 risk MDS has been debated. 
A retrospective cytogenetic multi- centre Spanish study found the 
erythroid response differed significantly if one aberration in addi-
tion to the 5q- was present, but the IPSS risk category was not evalu-
ated.11 In the present study, a good response rate was observed even 
when an additional chromosomal change accompanied del(5q), thus 
emphasising similarities between isolated del(5q) and del(5q) plus 
one additional anomaly, as recently recognised by the WHO 2016.12 
Remarkably, in our series, all cases belonged to LOW or INT1 IPSS 
category. This may be relevant considering that around 43% of LOW 
and INT1 MDS without del(5q) responded to LEN.13 Consequently, 
LEN appears optimal treatment for LOW and INT1 MDS with iso-
lated del(5q), or del(5q) plus one more change.
Overall, evolution rate (15,6%) in this Registry study was lower 
than the rate of 25,4% in the MDS- 004 European study3 although 
they had comparable observation time (44 months vs 35.5 months 
in the LEN 5 mg group and 36.9 months in the LEN 10 mg group) and 
baseline cytogenetics. In his update of 148 cases, including 16,9% 
F IGURE  2 Time to development of complete (A) and overall 
cytogenetic response (B) in Group A (data are referred to first 
24 mo of treatment); cytogenetic response by treatment group for 
the first 48 mo of treatment (C) [Colour figure can be viewed at 
wileyonlinelibrary.com]
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with one more change and 8,1% with complex 5q- , List et al14 found 
AML evolution in 28.6% of cases 5 years after treatment initiation. 
Median time of progression was not reached for patients with iso-
lated 5q- , while it was 4.1 years for patients with additional cyto-
genetic abnormalities. A retrospective study reported no significant 
difference in the AML evolution rate in 125 untreated and 295 
treated cases with isolated del(5q).15 AML evolution was observed 
in 12.6% of 381 internationally recruited untreated cases with hae-
matological and cytogenetic features similar to those in our study, 
namely low- int1 risk MDS, a low proportion of complex karyotypes 
(4.2%) a low proportion of 5q- plus another aberration (14.2%), a me-
dian observation time of 49.8 months.16
In this study, cases developing AML and those progressing to 
higher risk MDS were both negative for any cytogenetic response 
to LEN treatment. Clonal progression and development of a com-
plex karyotype in 7/13 cases corresponded to AML development, 
whereas complex cytogenetics and new cytogenetic aberrations 
never appeared when MDS evolved towards a higher risk category. 
Although this observation needs to be confirmed in larger series of 
cases, our cytogenetic findings suggest that different biological fea-
tures underlie disease progression to either worsening MDS or AML.
Unfortunately, biological samples were not available to evalu-
ate molecular prognostic factors predictive of lower cytogenetic 
response or disease evolution, such as p53 expression or muta-
tions,17,18 TET2, ASXL1, RUNX1 and CSNK1A1 mutations,19,20 or 
the expression of cereblon, whose reduction correlates with LEN 
resistance.21
In conclusion, this “real life” Registry showed that LEN treatment 
successfully achieved a high erythroid response rate and reduced 
transfusion dependence in Low- Int1 risk MDS with del(5q), both as 
sole anomaly or associated with one change. The leukemic evolu-
tion rate was similar to that observed in other multi- centre studies. 
Cytogenetic results emphasised biological differences in cases with 
evolution to AML or to higher risk MDS. International efforts should 
be made to investigate predictive biological markers in large- scale 
clinical studies.
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Molinette San Giovanni Battista di Torino, Sezione Ematologia (Dario 
Ferrero, Stefano D’Ardia); Ospedale Mauriziano Umberto I, Torino 
(Corrado Tarella); Ospedale “Casa Sollievo della Sofferenza” IRCCS di 
S. Giovanni Rotondo, Sezione Ematologia (Nicola Cascavilla); Azienda 
ULSS 12 Veneziana, sezione Ematologia (Renato Bassan, Rosaria 
Sancetta); Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico Milano, Sezione di Ematologia (Agostino Cortelezzi, 
Gianluigi Reda); Ospedale “A.Tortona” di Pagani, Medicina Interna e 
Oncoematologia (Alfonso Maria D’Arco); Ospedale Sant’Eugenio, 
Unità di Ematologia (Paolo De Fabritiis); Ospedale Vito Fazzi di Lecce, 
sezione Ematologia (Nicola Di Renzo); Università Degli Studi di 
Perugia, Sezione Ematologia (Brunangelo Falini); Ematologia 
Università “Sapienza” Roma (Giuliana Alimena); Arcispedale Santa 
Maria Nuova di Reggio Emilia, sezione Ematologia (Paolo Avanzini, 
Fiorella Ilariucci); Ospedale Nicola Gianettasio di Rossano Calabro, 
Cosenza, sezione Oncologia (Francesco Iuliano); ASL Cagliari Presidio 
Ospedaliero Roberto Binaghi, Sezione Ematologia (Giorgio La Nasa, 
Giovanni Caocci); Ospedale Policlinico Santa Maria alle Scotte di 
Siena, sezione Ematologia (Marzia Defina); Ospedale San Francesco di 
Nuoro, sezione Ematologia (Giancarlo Latte, Angelo Palmas); Azienda 
Ospedaliera Nazionale “SS. Antonio e Biagio e C. Arrigo” di Alessandria 
Struttura Complessa di Ematologia (Alessandro Levis); Policlinico 
Agostino Gemelli Roma, Ematologia (Giuseppe Leone, Maria Teresa 
Voso); Azienda Ospedaliero- Universitaria Ospedali Riuniti di Ancona, 
Sezione Ematologia (Pietro Leoni, Antonella Poloni); Azienda 
Ospedaliero Universitaria di Sassari, sezione Ematologia (Claudio 
Fozza); Azienda Ospedaliero Universitaria di Parma, Sezione 
Ematologia con Trapianto di Midollo Osseo (Monica Crugnola); ASL 
Viterbo, Stabilimento di Ronciglione, Day Hospital di Ematologia 
(Marco Montanaro); Azienda Socio Sanitaria Territoriale di Cremona, 
Ematologia (Pierangelo Spedini, Francesco Lanza); Azienda 
Ospedaliera di Potenza, Ematologia (Michele Pizzuti); Divisione di 
Ematologia - Dipartimento di Medicina Clinica e Chirurgica Università 
Federico II di Napoli (Fabrizio Pane); Azienda ULSS 18 Rovigo, Sezione 
Ematologia (Rossella Paolini); Clinica Ematologica CTA,Università 
degli Studi Milano Bicocca – Azienda Ospedaliera San Gerardo Monza 
(Lorenza Borin); Azienda Ospedaliera Papa Giovanni XXIII, Sezione di 
Ematologia, Bergamo (Alessandro Rambaldi); Presidio Ospedaliera di 
Brescia sezione Ematologia (Giuseppe Rossi, Anna Maria Pelizzari); 
Spedali Civili di Brescia sezione Trapianto di Midollo Osseo (Domenico 
Russo); Azienda ULSS 6 Vicenza, Ematologia (Anna D’Emilio, Marco 
Ruggeri); Azienda Ospedaliera di Padova, sezione di Ematologia 
(Giampietro Semenzato); Azienda Ospedaliera Policlinico Consorziale 
BARI, Ematologia Universitaria (Giorgina Specchia); USL Asolo, 
Sezione di Immunoematologia e Trasfusionale (Giuseppe Tagariello, 
Roberto Sartori); Ospedale Cardinal Massaia di Asti sezione Oncologia 
(Franco Testore, Giorgio Ciravegna); Policlinico di Modena, sezione 
Ematologia (Roberto Marasca); ULSS 1 Belluno, Sezione di Medicina 
Interna (Lorella Cimarosto, Orietta Fontanive); Ospedali Riuniti 
Pesaro, Ematologia e Centro Trapianti (Giuseppe Visani).
